.
MergerLinks Header Logo

Announced

Recipharm to acquire Arranta Bio from Ampersand Capital Partners.

Financials

Edit Data
Transaction Value-
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Single Bidder

Private Equity

Biotechnology

biotechnology company

Private

CDMO

Cross Border

Friendly

Pending

Majority

United States

Acquisition

Synopsis

Edit

Recipharm, a contract development and manufacturing organization, agreed to acquire Arranta Bio, a biotechnology company, from Ampersand Capital Partners, a private equity firm. Financial terms were not disclosed. “We welcome Arranta and its team of experts who boast a strong reputation in the CDMO industry. This acquisition is another important step for us in growing our biologics business and developing a strong presence into the US. We look forward to working closely with the Arranta team, building links across the wider Recipharm organisation to make this business a huge success," Marc Funk, Recipharm CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US